The global Apheresis Equipment market is projected to reach US$3.6 billion by 2024, driven by the increasing prevalence of blood disorders and chronic diseases requiring blood transfusion.
Apheresis refers to a procedure where blood from a person (patient or donor) is passed through a medical device in order to extract the required components, such as red blood cells, platelets, plasma and others. Apart from its use in separating specific blood components from donor blood, the apheresis process is also utilized for the treatment of specific diseases conditions such as leukemia. Global market for apheresis equipment continues to witness stable growth driven by the rising adoption of therapeutic and donor apheresis. The increasing prevalence of blood disorders such as sickle cell anemia, blood cancer, and hemophilia and the rising need for various blood products is driving the demand for apheresis equipment, globally. Specifically, the increasing incidence of various illnesses in the elderly and the subsequent rise in demand for blood and blood components is expected to foster market growth.
Growing awareness about platelet donation in developed economies and the subsequent growth in the number of platelet donors and increasing R&D investments of biopharmaceutical companies also contribute to apheresis market growth. Also driving growth is the increase in causality figures that is leading to enhanced need for surgical procedures that require blood transfusion. Rising awareness about apheresis blood collection and escalating demand for automated blood component separation procedures also favor growth in the apheresis equipment market. Technology advances such as automated interface system, continuous flow centrifugation and features such as screen navigation, GUI display, and custom anticoagulant infusion system are also expected to foster growth in the apheresis equipment market.
The United States represents the largest regional market, worldwide. Growth in the U.S. apheresis equipment market is driven by the rising incidence of hematological disorders and other chronic conditions such as neurological disorders and increasing demand for technologically advanced and automated products. Further, access to advanced healthcare services and favorable reimbursement framework also favors market growth. Asia-Pacific is forecast to grow at the fastest CAGR of 12.1% over the analysis period. The promising outlook for Asia-Pacific is attributed to the rising prevalence of blood-related disorders in emerging economies of China and India. Increase in surgical procedures and trauma and accident cases and improving healthcare infrastructure also bode well for the market.
Major players in the market include Asahi Kasei Medical Co. Ltd., B Braun Melsungen AG, Cerus Corporation, Fresenius Kabi, Haemonetics Corporation, Kaneka Corporation, Kawasumi Laboratories Inc., Mallinckrodt Pharmaceuticals, Medica SpA, NIKKISO Europe GmbH, and Terumo BCT Inc., among others.